Zelboraf, Cosentyx and Takecab Set For Japan Listing, Launch
This article was originally published in PharmAsia News
Executive Summary
Japan's granting of reimbursement prices to a batch of new drugs including Chugai's Zelboraf for melanoma, Novartis's Cosentyx for psoriasis and Takeda's gastrointestinal P-CAB inhibitor Takecab clears the way for the products’ commercial launch in the country.